PFS and OS in patients with aggressive NHL after CD19 CAR T-cell immunotherapy. Kaplan-Meier estimates of PFS (A) and OS (B) in patients with aggressive NHL who achieved CR (red) and in all patients (blue). The numbers of patients at risk at 6-month intervals are indicated.